DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...

The best-selling author and podcaster on how to preserve robust physical, cognitive and emotional health, and how Medicine ...

At the foundation of healthspan medicine are the pillars of health. These are easily understood through four simple verbs: ...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark ... although with different mechanisms of action there is potential for combination use. AZ has first mover advantage in chronic kidney ...

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 ... its mechanism of action and ...

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...

A new model of brain metabolism – the most complex ever generated –shows how altering key chemicals could restore aged cells ...